In the BioHarmony Drug Report Database

"Preview" Icon

Eculizumab

Soliris (eculizumab) is an antibody pharmaceutical. Eculizumab was first approved as Soliris on 2007-03-16. It is used to treat atypical hemolytic uremic syndrome and paroxysmal hemoglobinuria in the USA. It has been approved in Europe to treat paroxysmal hemoglobinuria. The pharmaceutical is active against complement C5.

 

Trade Name

 

Soliris
 

Common Name

 

eculizumab
 

ChEMBL ID

 

CHEMBL1201828
 

Indication

 

atypical hemolytic uremic syndrome, paroxysmal hemoglobinuria
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Eculizumab structure rendering